Navigation Links
Par Pharmaceutical to Launch meclizine HCL Tablets
Date:7/9/2008

WOODCLIFF LAKE, N.J., July 9 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it will commence shipment of 12.5mg and 25mg meclizine HCl tablets immediately. At this time, Par believes it is the exclusive supplier of the AB-rated generic product.

Par marketed meclizine prior to an explosion at the facility of its API supplier in February 2008. Par has since qualified a new API source and received the appropriate approval of its supplemental new drug application to manufacture and market meclizine HCl utilizing its new API supplier.

Important information about meclizine

Meclizine is an oral antiemetic indicated for the prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness. It is contraindicated in individuals who have shown a previous hypersensitivity to it.

About Par Pharmaceutical

Par Pharmaceutical, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit http://www.parpharm.com.

Safe Harbor Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to risks and uncertainties, including the extent and impact of litigation arising out of the accounting issues described in the Company's filings with the Securities and Exchange Commission (SEC), the difficulty of predicting FDA filings and approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, uncertainty of patent litigation filed against the Company, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks and uncertainties detailed from time to time in the company's filings with the SEC, such as the Company's reports on Form 10-K, Form 10-Q and Form 8-K, and amendments thereto. Any forward-looking statements included in this press release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
2. Lilly to Acquire SGX Pharmaceuticals
3. New MedPredict Report Highlights Trend Toward Early Diagnosis and Treatment of Rheumatoid Arthritis, Impact on Pharmaceutical Development
4. Pharmaceutical Institute, in Collaboration With Campbell Alliance, Releases Second Edition of Breakthrough Book on the Inner Workings of the Pharmaceutical Industry
5. Edison Pharmaceuticals Receives Commendation From the City of San Jose
6. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
7. Transcept Pharmaceuticals Appoints Key Senior Executives
8. Addrenex Pharmaceuticals Licenses New Compound to Sciele Pharma for the Treatment of Hypertension and Other Potential Indications
9. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
10. Webcast Alert: Isis Pharmaceuticals Announces a Business Update Conference Call
11. Par Pharmaceutical Receives Final Approval to Market Generic Marinol(R) CIII (Dronabinol) Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... , Jan. 21, 2017   Boston Biomedical , ... designed to target cancer stemness pathways, today presented data ... napabucasin, at the 2017 American Society of Clinical Oncology ... . In a Phase Ib/II ... designed to inhibit cancer stemness pathways by targeting STAT3 ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... today the next evolution in spinal fusion, the MISquito Percutaneous Pedicle Screw ... the competition, SpineFrontier is focused on technique driven product solutions that provide ...
(Date:1/19/2017)... Research and Markets ... the addition of the "Implantable Biomaterials Market Analysis ... report to their offering. Report Highlights: ... on current and future market trends to identify the investment opportunities ... base numbers Key market trends across the business segments, ...
(Date:1/19/2017)... 19, 2017 AquaBounty Technologies, Inc. (AIM: ABTU; ... in aquaculture and a majority-owned subsidiary of Intrexon Corporation ... completed the listing of its common shares on the ... Intrexon. "AquaBounty,s listing on NASDAQ represents an ... exposure to the U.S. markets as we advance plans ...
Breaking Biology Technology:
(Date:12/15/2016)... Mich. , Dec. 15, 2016  There is ... car doors or starting the engine. Continental will demonstrate ... Las Vegas . Through the combination ... Start and Entry) and biometric elements, the international technology ... of vehicle personalization and authentication. "The integration ...
(Date:12/12/2016)... Dec. 12, 2016  Researchers at Trinity College, ... graphene by combining the material with Silly Putty. The ... pressure detector able to sense pulse, blood pressure, ... spider.  The research team,s findings ... read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/8/2016)... 8, 2016  Singulex, Inc., the leader in Next ... into a license and supply agreement with Thermo Fisher ... provides Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), ... is used to diagnose systemic bacterial infection and sepsis ... to aid in assessing the risk of critically ill ...
Breaking Biology News(10 mins):